,
,
,
,
,
Rôle de l'expression PDL1 sur la survie globale et la survie sans progression ,
,
, 47 1. Facteurs influençant la survie globale et la survie sans progression
,
,
,
,
,
,
,
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012, Int J Cancer, vol.136, issue.5, pp.359-86, 2015. ,
, chiffres -Cancer du poumon | Institut National Du Cancer, Jul30, 2017.
Major changes in lung cancer over the last ten years in France: the KBP-CPHG studies ,
KBP-2010-CPHG: Characteristics and management of 6,083 new cases of non-small-cell-lung-cancer (NSCLC), Eur Respir J, vol.40, issue.Suppl56, p.3128, 2012. ,
The 2004 World Health Organization classification of lung tumors, Seminars in Roentgenology, vol.40, 2005. ,
The Treatment of Inoperable Sarcoma by Bacterial Toxins (the Mixed Toxins of the Streptococcus erysipelas and the Bacillus prodigiosus), Proc R Soc Med, vol.3, pp.1-48, 1910. ,
Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion, Science, vol.331, issue.6024, pp.1565-70, 2011. ,
Hallmarks of cancer: the next generation, Cell, vol.144, issue.5, p.646, 2011. ,
Oncology meets immunology: the cancer-immunity cycle, Immunity, vol.39, issue.1, pp.1-10, 2013. ,
PD-1 and Its Ligands in Tolerance and Immunity, Annu Rev Immunol, vol.26, issue.1, pp.677-704, 2008. ,
The blockade of immune checkpoints in cancer immunotherapy, Nat Rev Cancer, vol.12, issue.4, pp.252-64, 2012. ,
Molecular pathways: next-generation immunotherapy ,
Targeting the PD-1/B7-H1(PD-L1) pathway to activateanti-tumor immunity, Curr Opin Immunol, vol.24, issue.2, pp.207-219, 2012. ,
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer, N Engl J Med, 2015. ,
Nivolumab versusDocetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer, N Engl J Med, 652015. ,
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial, Lancet, vol.387, pp.1540-50, 2016. ,
Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer, N Engl J Med, vol.375, pp.1823-1856, 2016. ,
Évaluation de l'expression de PD-L1 en immunohistochimie : un biomarqueur émergent dans les carcinomes pulmonaires non à petites cellules, Ann Pathol, vol.36, issue.1, pp.94-102, 2016. ,
DOI : 10.1016/j.annpat.2015.11.004
Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer, vol.29, pp.953-958, 2018. ,
PD-L1 Immunohistochemistry assays for lung cancer: results from phase 1 of the « Blueprint PD-L1 IHC Assay Comparison Project, J Thorac Oncol, vol.12, p.1, 2016. ,
A pooled analysis of nivolumab for the treatment of advanced non-small-cell lung cancer and the role of PD-L1 as a predictive biomarker, Immunotherapy, vol.8, issue.9, pp.1011-1020, 2016. ,
,
Mis en ligne le 30 ,
Programmed death-ligand 1 immunohis-tochemistry in lung cancer: in what state is this art?, JThorac Oncol, vol.10, pp.985-994, 2015. ,
Immune-based mechanisms of cytotoxic chemotherapy: implicationsfor the design of novel and rationale-based combined treat-ments against cancer, Cell Death Differ, vol.21, pp.15-25, 2014. ,
, , vol.8, pp.479-88, 2016.
, The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis
Moro-Sibilo immunotherapy dans les CBNPC, 2017. ,
Predictive markers for the efficacy of antiPD1/PDL1 antibodies in lung cancer, J Thorac Oncol, vol.11, pp.976-88, 2016. ,
Real-life use of nivolumab in non small cell lung cancer: a multicentric cohorte to determine its clinical efficacy and predictive factor of early progression, ASCO 2017, 2017. ,
Italian cohort of nivolumab Expanded Access Programme (EAP): Preliminary data from a real-world population, Abstract, vol.3067, 2017. ,
, Updated Dataset assessing Tumor Mutation Burden (TMB) as a biomarker for response to PD-1/PD-L1 Targeted Therapies in Lung Cancer ( LC) Siraj Ali and al, Foundation Medicine
PD-1 blockade induces responses by inhibi-ting adaptive immune resistance, Nature, vol.515, pp.568-71, 2014. ,
DOI : 10.1038/nature13954
URL : http://europepmc.org/articles/pmc4246418?pdf=render
Tobacco smoke carcinogens, DNA damage andp53 mutations in smoking-associated cancers, Oncogene, vol.21, issue.48, pp.7435-51, 2002. ,
DOI : 10.1038/sj.onc.1205803
URL : https://www.nature.com/articles/1205803.pdf
, La charge mutationnelle. Correspondances en oncothéranostic vol VI, vol.3, 2009.
, Prise en charge des effets secondaires (digestifs et pulmonaires) au Nivolumab selon l, Annexe, vol.5